Artwork

Content provided by Clinical Care Options, LLC and Clinical Care Options. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clinical Care Options, LLC and Clinical Care Options or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Experts Discuss Challenges in Advanced Hepatocellular Carcinoma Management

26:12
 
Share
 

Manage episode 338649472 series 3256997
Content provided by Clinical Care Options, LLC and Clinical Care Options. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clinical Care Options, LLC and Clinical Care Options or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In this podcast episode from Clinical Care Options (CCO), Heinz-Josef Klumpen, MD, PhD, and Chris Verslype, MD, PhD, discuss challenges in selecting and sequencing therapy for patients with advanced hepatocellular carcinoma. Topics include:

  • Factors to consider before selecting frontline immunotherapy
  • Role of TKIs in the frontline
  • Impact of Child-Pugh status on the efficacy of immunotherapy/VEGF inhibitor combination therapy
  • Real-world evidence on frontline immunotherapy/VEGF combination therapy
  • Factors to consider when selecting second-line therapy including the role of TKIs and planning for multiple lines of therapy

Presenters:

Heinz-Josef Klumpen, MD, PhD
Staff Specialist, Medical Oncologist
Department of Medical Oncology
Amsterdam UMC
Amsterdam, The Netherlands

Chris Verslype, MD, PhD
Professor
Clinical Digestive Oncology
KULeuven
Head of Clinic
Hepatology
Digestive Oncology
U.Z. Leuven
Leuven, Belgium

  continue reading

185 episodes

Artwork
iconShare
 
Manage episode 338649472 series 3256997
Content provided by Clinical Care Options, LLC and Clinical Care Options. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clinical Care Options, LLC and Clinical Care Options or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In this podcast episode from Clinical Care Options (CCO), Heinz-Josef Klumpen, MD, PhD, and Chris Verslype, MD, PhD, discuss challenges in selecting and sequencing therapy for patients with advanced hepatocellular carcinoma. Topics include:

  • Factors to consider before selecting frontline immunotherapy
  • Role of TKIs in the frontline
  • Impact of Child-Pugh status on the efficacy of immunotherapy/VEGF inhibitor combination therapy
  • Real-world evidence on frontline immunotherapy/VEGF combination therapy
  • Factors to consider when selecting second-line therapy including the role of TKIs and planning for multiple lines of therapy

Presenters:

Heinz-Josef Klumpen, MD, PhD
Staff Specialist, Medical Oncologist
Department of Medical Oncology
Amsterdam UMC
Amsterdam, The Netherlands

Chris Verslype, MD, PhD
Professor
Clinical Digestive Oncology
KULeuven
Head of Clinic
Hepatology
Digestive Oncology
U.Z. Leuven
Leuven, Belgium

  continue reading

185 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide